Cancer biomarker Market and Its Impact on Personalized Therapy
The Cancer biomarker Market is transforming cancer treatment by supporting personalized therapy approaches. Biomarkers allow clinicians to identify which treatments will work best for individual patients, minimizing side effects and maximizing effectiveness.
In oncology, targeted therapies informed by biomarkers are improving outcomes in breast, lung, and colorectal cancers. With more pharmaceutical companies focusing on biomarker-driven drug development, personalized therapy is becoming mainstream.
Market Outlook: Valued at USD 15.9 billion in 2022, the cancer biomarker market is set to reach USD 27.8 billion by 2030, growing at a 9.8% CAGR.
1 View